Blog

Christiana Bardon: The AACR industry partnering event was a tremendous success

Photo from Christiana Bardon/LinkedIn

Apr 9, 2024, 12:53

Christiana Bardon: The AACR industry partnering event was a tremendous success

Christiana Bardon, Co-Managing Partner at MPM BioImpact, shared on their LinkedIn:

”The American Association for Cancer Research (AACR) industry partnering event was a tremendous success! I can’t believe that we had the oncology heads of every major pharma company there to share their pipelines. Here are a few of my observations after listening to these brilliant minds:

ADC is definitely the hottest platform across the entire industry. What’s exciting are not only the new targets, but also the new payloads being developed such as degraders. We still have so much to learn about this platform, though. I was shocked when Raffaele Colombo explained to us that less than 1% of ADCs actually get into the tumor!!!
Radio ligand therapy is just beginning as a major new class of the therapeutics and is the next major trend.
Combination therapy will continue to be the mainstay of oncology drug treatment. Future combinations, however, will Include new technologies such as ADCs and cell therapy.
Noticeably absent from pipelines were second generation I/O targets
Vaccines and novel cart T therapies are TBD
AI is having a growing impact in drug development although ChatGPT ‘how to cure cancer’ doesn’t yet quite work
Rick Pazdur of the FDA explained dose optimization and many new FDA projects. He takes a common sense and no nonsense approach which I admire.

Special thanks to Leerink Partners, Royalty Pharma, MPM BioImpact and the City of Hope for their support! And of course my fantastic co moderators Michael Caligiuri and Bill Hait!”

Source: Christiana Bardon/LinkedIn

ADC American Association for Cancer Research Bill Hait cancer Cell Therapy Christiana Bardon City of Hope combination therapy drug treatment FDA Leerink Partners Michael Caligiuri MPM BioImpact new targets OncoDaily Oncology Radio ligand therapy Raffaele Colombo Rick Pazdur Royalty Pharma

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage